Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir Add-on to Lamivudine in HIV/HBV Co-infection
NCT00051038Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2002
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatitis B (HBV) comparing Entecavir Arm with Placebo Arm (2 arms). Primary endpoint: Mean change from baseline in HBV DNA at 24 weeks. Started Sep 2002; status: completed.
02
Drugs
entecavir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00051038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051038.